Table 1.
Antimicrobial susceptibility tests of 17 carbapenem-resistant K. pneumoniae isolates from urine at Taipei Medical University Hospital.
| Isolate | Ward 4 | Age | Isolated Date | CMZ 1 | CAZ 1 | CRO 1 | FEP1 | IMP 1 | MEM 1 | ETP 1 | GEN 1 | AMK 1 | CIP 1 | LVX 1 | SXT 1 | TZP 1 | COL 1 | TGC 2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1050022 | Ward 7 | 68 | 3 December 2016 | R (≥32) | R (>16) | I (32) | S (≤2) | R (4) | S (≤1) | R (>4) | R (>8) | S (≤8) | S (≤0.5) | S (≤1) | R (>2/38) | R (>64/4) | WT (1) | S (0.5) |
| T1060027 | ER | 82 | 4 January 2017 | R (≥32) | I (8) | R (>32) | R (>16) | I 3 | S (≤1) | R (>4) | R (>8) | S (≤8) | R (>2) | R (>4) | S 3 | R (>64/4) | WT (1) | S (1) |
| T1060063 | ER | 88 | 13 February 2017 | R (≥32) | R (>16) | I (16) | S (≤2) | R (8) | I (2) | R (>4) | R (>8) | S (≤8) | S (1) | S (≤1) | R (>2/38) | R (>64/4) | WT (1) | S (0.19) |
| T1060125 | Ward 10B | 65 | 21 March 2017 | R (≥32) | R (>16) | R (>32) | R (>16) | R (> 8) | R (>8) | R (>4) | R (>8) | R (>32) | R (>2) | R (>4) | S (≤0.5/9.5) | R (>64/4) | WT (1) | S (0.5) |
| T1060144 | Ward 8B | 89 | 4 April 2017 | I (32) | R (>16) | R (>32) | R (>16) | R (8) | R (4) | R (4) | R (>8) | S (≤8) | S (1) | S (≤1) | R (>2/38) | R (>64/4) | WT (1) | S (0.75) |
| T1060283 | Ward 8A | 95 | 20 June 2017 | R (≥32) | R (>16) | R (>32) | R (>16) | I3 | S (≤1) | I (1) | R (>8) | R (>32) | R (>2) | R (>4) | R (>2/38) | R (>64/4) | WT (1) | S (0.75) |
| T1060372 | OPD | 54 | 2 August 2017 | R (≥32) | R (>16) | S (≤1) | S (≤1) | R (4) | S (≤0.25) | S (0.5) | R (>8) | S (≤8) | S (1) | S (≤1) | R (>2/38) | S (≤4/4) | WT (1) | S (1) |
| T1060383 | ER | 88 | 6 August 2017 | R (≥32) | R (>16) | S (≤1) | S (≤1) | I (2) | S (≤0.25) | S (≤0.25) | R (>8) | S (≤8) | R (>2) | R (>4) | S (≤0.5/9.5) | S (≤4/4) | WT (1) | S (0.38) |
| T1060393 | Ward 8B | 79 | 14 August 2017 | I (32) | R (>16) | R (>32) | R (>16) | R (> 4) | R (>4) | R (2) | R (>8) | R (>32) | S (1) | S (≤1) | R (>2/38) | R (≥64/4) | WT (≤0.25) | S (0.5) |
| T1060405 5 | ER | 81 | 17 August 2017 | R (≥32) | R (>16) | R (16) | S (≤1) | R (4) | S (≤0.25) | I (1) | S (≤2) | S (≤8) | R (>2) | R (>4) | R (>2/38) | I (64/4) | NWT (16) | R (2) |
| T1060412 | OPD | 93 | 15 August 2017 | R (≥32) | R (>16) | I (2) | S (2) | R (> 4) | R (4) | R (>4) | S (≤2) | S (16) | R (>2) | R (>4) | S (≤0.5/9.5) | R (≥64/4) | WT (≤0.25) | S (0.25) |
| T1060431 5 | ER | 81 | 26 August 2017 | R (≥32) | R (>16) | R (32) | S (2) | R (> 4) | I (2) | R (>4) | S (≤2) | S (≤8) | R (>2) | R (>4) | R (>2/38) | R (≥64/4) | NWT (8) | R (2) |
| T1060449 | Ward 8 | 55 | 5 September 2017 | R (≥32) | S (4) | S (≤1) | S (≤1) | R (4) | S (≤0.25) | S (0.5) | R (>8) | S (≤8) | S (1) | S (≤1) | R (>2/38) | S (≤4/4) | WT (0.5) | I (1.5) |
| T1060495 | OPD | 47 | 28 September 2017 | R (≥ 32) | R (>16) | R (>32) | I (8) | I (2) | S (≤0.25) | S (0.5) | R (>8) | S (≤8) | S (1) | S (≤1) | R (>2/38) | I (64/4) | WT (0.5) | S (0.75) |
| T1060497 | ER | 73 | 25 September 2017 | R (≥32) | I (8) | R (>32) | I (8) | I3 | S (≤0.25) | R (2) | S (≤2) | S (≤8) | R (>2) | R (>4) | S (≤0.5/9.5) | S (≤4/4) | WT (0.5) | S (0.75) |
| T1060498 | OPD | 86 | 20 September 2017 | R (≥32) | R (>16) | R (32) | S (≤1) | I 3 | R 3 | R (≥2) | R (>8) | S (≤8) | I (2) | S (≤1) | R (>2/38) | I (64/4) | WT (0.5) | S (0.25) |
| T1060500 | OPD | 64 | 22 September 2017 | R (≥32) | S (2) | S (≤1) | S (≤1) | R (4) | S (≤0.25) | S (≤0.25) | S (≤2) | S (≤8) | S (1) | S (≤1) | R (>2/38) | S (≤4/4) | WT (0.5) | I (1.5) |
| Susceptibility Frequency (%) | 0% (0/17) |
11.8% (2/17) |
23.5% (4/17) |
58.8% (10/17) |
0% (0/17) |
58.8% (10/17) |
29.4% (5/17) |
29.4% (5/17) |
82.4% (14/17) |
47.1% (8/17) |
52.9% (9/17) |
29.4% (5/17) |
29.4% (5/17) |
88.2% (15/17) |
76.5% (13/17) |
1 Minimal inhibitory concentrations (MICs) of antibiotics except tigecycline were determined by using the microbroth dilution method and interpreted according to Enterobacteriaceae in the CLSI guideline (2018). The MIC values are shown in parentheses. 2 The susceptibility of tigecycline was determined by using ETEST® and interpreted based on the EUCAST guideline (2018). The cutoff breakpoint for susceptibility to tigecycline was equal to or less than 1 μg/mL, whereas the MIC value was equal to or more than 2 μg/mL for resistance to tigecycline. 3 Interpretation without MIC values was verified by using disk diffusion methods. 4 OPD: outpatient department; ER: emergency room. 5 These two strains were isolated from the same patient.